BioPharma Credit (BPCR) Competitors

BioPharma Credit logo
GBX 0.98 -0.01 (-1.41%)
As of 11/20/2026 12:11 PM Eastern

BPCR vs. ASLI, ANIC, LGT, RIV, and SGEM

Should you buy BioPharma Credit stock or one of its competitors? BioPharma Credit's main competitors and comparable companies include abrdn European Logistics Income (ASLI), Agronomics (ANIC), Lighthouse Group (LGT), River and Mercantile Group (RIV), and ScotGems (SGEM). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "asset management & custody banks" industry.

How does BioPharma Credit compare to abrdn European Logistics Income?

abrdn European Logistics Income (LON:ASLI) and BioPharma Credit (LON:BPCR) are both small-cap finance companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, media sentiment, risk, institutional ownership, valuation, dividends, earnings and analyst recommendations.

abrdn European Logistics Income has a beta of 0.797, meaning that its stock price is 20% less volatile than the broader market. Comparatively, BioPharma Credit has a beta of 0.22688746, meaning that its stock price is 77% less volatile than the broader market.

6.3% of abrdn European Logistics Income shares are held by institutional investors. Comparatively, 31.8% of BioPharma Credit shares are held by institutional investors. 0.1% of abrdn European Logistics Income shares are held by company insiders. Comparatively, 0.1% of BioPharma Credit shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, abrdn European Logistics Income's average media sentiment score of 0.00 equaled BioPharma Credit'saverage media sentiment score.

Company Overall Sentiment
abrdn European Logistics Income Neutral
BioPharma Credit Neutral

BioPharma Credit has a net margin of 89.20% compared to abrdn European Logistics Income's net margin of -214.42%. BioPharma Credit's return on equity of 9.39% beat abrdn European Logistics Income's return on equity.

Company Net Margins Return on Equity Return on Assets
abrdn European Logistics Income-214.42% -19.46% 1.88%
BioPharma Credit 89.20%9.39%4.98%

abrdn European Logistics Income pays an annual dividend of GBX 8.92 per share and has a dividend yield of 85.8%. BioPharma Credit pays an annual dividend of GBX 7 per share and has a dividend yield of 715.7%. abrdn European Logistics Income pays out -153.8% of its earnings in the form of a dividend. BioPharma Credit pays out 73.4% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

BioPharma Credit has higher revenue and earnings than abrdn European Logistics Income. abrdn European Logistics Income is trading at a lower price-to-earnings ratio than BioPharma Credit, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
abrdn European Logistics Income-£15.46M-2.77-£79.93M-£5.80N/A
BioPharma Credit£110.03M0.10£10.42B£9.540.10

Summary

BioPharma Credit beats abrdn European Logistics Income on 11 of the 13 factors compared between the two stocks.

How does BioPharma Credit compare to Agronomics?

Agronomics (LON:ANIC) and BioPharma Credit (LON:BPCR) are both small-cap finance companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, risk, profitability, earnings, dividends, analyst recommendations, valuation and institutional ownership.

Agronomics has a net margin of 345.75% compared to BioPharma Credit's net margin of 89.20%. BioPharma Credit's return on equity of 9.39% beat Agronomics' return on equity.

Company Net Margins Return on Equity Return on Assets
Agronomics345.75% -12.24% 2.20%
BioPharma Credit 89.20%9.39%4.98%

0.6% of Agronomics shares are owned by institutional investors. Comparatively, 31.8% of BioPharma Credit shares are owned by institutional investors. 19.9% of Agronomics shares are owned by insiders. Comparatively, 0.1% of BioPharma Credit shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Agronomics currently has a consensus price target of GBX 13.30, indicating a potential upside of 238.25%. Given Agronomics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Agronomics is more favorable than BioPharma Credit.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Agronomics
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
BioPharma Credit
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

In the previous week, Agronomics' average media sentiment score of 0.00 equaled BioPharma Credit'saverage media sentiment score.

Company Overall Sentiment
Agronomics Neutral
BioPharma Credit Neutral

BioPharma Credit has higher revenue and earnings than Agronomics. Agronomics is trading at a lower price-to-earnings ratio than BioPharma Credit, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Agronomics-£11.92M-3.58-£436.90K-£1.60N/A
BioPharma Credit£110.03M0.10£10.42B£9.540.10

Agronomics has a beta of 0.983, suggesting that its stock price is 2% less volatile than the broader market. Comparatively, BioPharma Credit has a beta of 0.22688746, suggesting that its stock price is 77% less volatile than the broader market.

Summary

BioPharma Credit beats Agronomics on 8 of the 14 factors compared between the two stocks.

How does BioPharma Credit compare to Lighthouse Group?

Lighthouse Group (LON:LGT) and BioPharma Credit (LON:BPCR) are both small-cap finance companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, risk, earnings, media sentiment, dividends, valuation and profitability.

31.8% of BioPharma Credit shares are owned by institutional investors. 0.1% of BioPharma Credit shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, Lighthouse Group's average media sentiment score of 0.00 equaled BioPharma Credit'saverage media sentiment score.

Company Overall Sentiment
Lighthouse Group Neutral
BioPharma Credit Neutral

BioPharma Credit has higher revenue and earnings than Lighthouse Group. Lighthouse Group is trading at a lower price-to-earnings ratio than BioPharma Credit, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Lighthouse Group£53.42M0.00N/A£1.80N/A
BioPharma Credit£110.03M0.10£10.42B£9.540.10

BioPharma Credit has a net margin of 89.20% compared to Lighthouse Group's net margin of 0.00%. BioPharma Credit's return on equity of 9.39% beat Lighthouse Group's return on equity.

Company Net Margins Return on Equity Return on Assets
Lighthouse GroupN/A N/A N/A
BioPharma Credit 89.20%9.39%4.98%

Lighthouse Group pays an annual dividend of GBX 0.01 per share. BioPharma Credit pays an annual dividend of GBX 7 per share and has a dividend yield of 715.7%. Lighthouse Group pays out 0.6% of its earnings in the form of a dividend. BioPharma Credit pays out 73.4% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

Summary

BioPharma Credit beats Lighthouse Group on 8 of the 10 factors compared between the two stocks.

How does BioPharma Credit compare to River and Mercantile Group?

BioPharma Credit (LON:BPCR) and River and Mercantile Group (LON:RIV) are both small-cap finance companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, risk, valuation, media sentiment, analyst recommendations, institutional ownership and dividends.

In the previous week, BioPharma Credit's average media sentiment score of 0.00 equaled River and Mercantile Group'saverage media sentiment score.

Company Overall Sentiment
BioPharma Credit Neutral
River and Mercantile Group Neutral

BioPharma Credit has higher revenue and earnings than River and Mercantile Group. River and Mercantile Group is trading at a lower price-to-earnings ratio than BioPharma Credit, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BioPharma Credit£110.03M0.10£10.42B£9.540.10
River and Mercantile Group£74.82M0.00N/A-£2.20N/A

BioPharma Credit pays an annual dividend of GBX 7 per share and has a dividend yield of 715.7%. River and Mercantile Group pays an annual dividend of GBX 0.09 per share. BioPharma Credit pays out 73.4% of its earnings in the form of a dividend. River and Mercantile Group pays out -4.1% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

31.8% of BioPharma Credit shares are owned by institutional investors. 0.1% of BioPharma Credit shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

BioPharma Credit has a net margin of 89.20% compared to River and Mercantile Group's net margin of 0.00%. BioPharma Credit's return on equity of 9.39% beat River and Mercantile Group's return on equity.

Company Net Margins Return on Equity Return on Assets
BioPharma Credit89.20% 9.39% 4.98%
River and Mercantile Group N/A N/A N/A

Summary

BioPharma Credit beats River and Mercantile Group on 9 of the 10 factors compared between the two stocks.

How does BioPharma Credit compare to ScotGems?

BioPharma Credit (LON:BPCR) and ScotGems (LON:SGEM) are both small-cap finance companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, valuation, profitability, risk, dividends, earnings and analyst recommendations.

BioPharma Credit has higher revenue and earnings than ScotGems. ScotGems is trading at a lower price-to-earnings ratio than BioPharma Credit, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BioPharma Credit£110.03M0.10£10.42B£9.540.10
ScotGems£5.07M0.00N/A£0.07N/A

In the previous week, BioPharma Credit's average media sentiment score of 0.00 equaled ScotGems'average media sentiment score.

Company Overall Sentiment
BioPharma Credit Neutral
ScotGems Neutral

BioPharma Credit has a net margin of 89.20% compared to ScotGems' net margin of 0.00%. BioPharma Credit's return on equity of 9.39% beat ScotGems' return on equity.

Company Net Margins Return on Equity Return on Assets
BioPharma Credit89.20% 9.39% 4.98%
ScotGems N/A N/A N/A

BioPharma Credit pays an annual dividend of GBX 7 per share and has a dividend yield of 715.7%. ScotGems pays an annual dividend of GBX 4 per share. BioPharma Credit pays out 73.4% of its earnings in the form of a dividend. ScotGems pays out 5,714.3% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. BioPharma Credit is clearly the better dividend stock, given its higher yield and lower payout ratio.

31.8% of BioPharma Credit shares are owned by institutional investors. 0.1% of BioPharma Credit shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

BioPharma Credit beats ScotGems on 9 of the 10 factors compared between the two stocks.

Get BioPharma Credit News Delivered to You Automatically

Sign up to receive the latest news and ratings for BPCR and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BPCR vs. The Competition

MetricBioPharma CreditCapital Markets IndustryFinance SectorLON Exchange
Market Cap£10.98M£4.27B£12.35B£2.67B
Dividend Yield7.10%5.69%5.05%5.11%
P/E Ratio0.1023.3219.4422.78
Price / Sales0.108.185.194.91
Price / Cash1.1929.1519.7220.23
Price / Book0.011.671.712.40
Net Income£10.42B£419.50M£1.32B£5.88B
7 Day Performance-0.81%-4.23%-4.23%-3.59%
1 Month Performance0.62%-4.26%-4.45%-3.91%
1 Year Performance10.38%-4.18%2.12%5.17%

BioPharma Credit Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BPCR
BioPharma Credit
N/AGBX 0.98
-1.4%
N/A+10.4%£10.98M£110.03M0.10N/A
ASLI
abrdn European Logistics Income
N/AGBX 10.70
+0.9%
N/A-70.9%£44.10M-£15.46MN/AN/A
ANIC
Agronomics
N/AGBX 4
+2.6%
GBX 13.30
+232.5%
-46.1%£43.34M-£11.92MN/AN/A
LGT
Lighthouse Group
N/AN/AN/AN/A£42.46M£53.42M18.47156
RIV
River and Mercantile Group
N/AN/AN/AN/A£42.40M£74.82MN/A300

Related Companies and Tools


This page (LON:BPCR) was last updated on 11/22/2026 by MarketBeat.com Staff.
From Our Partners